Crispr Therapeutics AG (CRSP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.10B
Last updated: Nov 17, 2026 at 4:36 PM ET
Crispr Therapeutics AG (CRSP) Stock Chart
Crispr Therapeutics AG (CRSP) has a latest price of $40.15 on Nov 17, 2026, 36.7% below its 52-week high of $63.45. Its price fell 23.6% over the past 12 months. The month-end price rose 181.8% over the 10 years through Oct 2026, a compound annual rate of 10.9%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $165.70 in Jan 2021 and its lowest $13.62 in May 2017, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart CRSP with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for CRSP.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 32.9%, and over 6 months it fell 15.6%. The month-end price rose 32.1% over the 3 years through Oct 2026, a compound annual rate of 9.7%.
| Period | Change |
|---|---|
| 1 month | -19.8% |
| 3 months | -32.9% |
| 6 months | -15.6% |
| 12 months | -23.6% |
| 12 months, with dividends | -23.6% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +32.1% | +9.7% |
| 5 years | -43.7% | -10.9% |
| 10 years | +181.8% | +10.9% |
Price by Year
Its best calendar year was 2020, when the price rose 151.4%, and its weakest was 2021, when it fell 50.5%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $51.42 | -1.9% |
| 2025 | $52.44 | +33.2% |
| 2024 | $39.36 | -37.1% |
| 2023 | $62.60 | +54.0% |
| 2022 | $40.65 | -46.4% |
| 2021 | $75.78 | -50.5% |
| 2020 | $153.11 | +151.4% |
| 2019 | $60.91 | +113.2% |
| 2018 | $28.57 | +21.7% |
| 2017 | $23.48 | +15.9% |
Trading Range
The price is 22.0% below its 50-day average of $51.49 and 23.4% below its 200-day average of $52.42.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $40.15 | |
| 52-week high | $63.45 | -36.7% |
| 52-week low | $39.83 | +0.8% |
| 50-day average | $51.49 | -22.0% |
| 200-day average | $52.42 | -23.4% |
Price Risk
Over 3 years, its largest fall from a peak was 64.9%.
| Measure | Value |
|---|---|
| 1-year beta | 1.86 |
| Largest fall, 1 year | -35.1% |
| Largest fall, 3 years | -64.9% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About CRSP
What is CRSP's 1-year price change?
Crispr Therapeutics AG's price fell 23.6% over the past 12 months. With dividends included, the 12-month total return was -23.6%.
What is CRSP's 5-year price change?
Crispr Therapeutics AG's month-end price fell 43.7% over the 5 years through Oct 2026, a compound annual decline of 10.9%. These figures leave out dividends.
What is CRSP's 52-week high and low?
Crispr Therapeutics AG's 52-week high is $63.45 and its 52-week low is $39.83. Its latest price of $40.15 on Nov 17, 2026 is 36.7% below the high.
What is CRSP's beta?
Crispr Therapeutics AG's 1-year beta against the S&P 500 is 1.86, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 35.1%.
Is the CRSP chart free?
Yes. Advanced Charting for CRSP is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
CRSP pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors